Funding for this research was provided by:
Deutsche Migräne- und Kopfschmerzgesellschaft
Eye on Vision Foundation
Baasch Medicus Foundation
Received: 3 September 2021
Accepted: 8 November 2021
First Online: 11 December 2021
: The study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of the Ludwig Maximillian’s University Munich (227–15). All study participants gave written informed consent for participation.
: Consent for publication was obtained from each study participant.
: Dr. Eren reports grants from the Friedrich-Baur Foundation, Deutsche Migräne- und Kopfschmerzgesellschaft during the performance of the study and Novartis outside the submitted work.PD Dr. Ruscheweyh reports personal fees and/or other from Allergan, Novartis, Lilly, Teva and Hormosan outside the submitted work.Prof. Dr. Straube reports personal fees from Allergan, Bayer, Sanofi, Desitin, Electrocore, Eli Lilly, Teva Pharmaceuticals, and grants from the German Research Council, Kröner-Fresenius Foundation, Ludwig-Maximilian University, Friedrich-Baur Foundation outside the submitted work.Prof. Dr. Schankin reports grants from Deutsche Migräne- und Kopfschmerzgesellschaft, Eye on Vision Foundation, Baasch Medicus Foundation during the conduct of the study; personal fees from Novartis, Eli Lilly, TEVA Pharmaceuticals, Lundbeck, Allergan, Almirall, Amgen, MindMed, Grünenthal outside the submitted work. He is a part-time employee at Zynnon.Dr. F. Schöberl declares no conflict of interest.Dr. T. Eggert declares no conflict of interest.